Recently, in vitro and in vivo targeting of MEK, ERK, PI3K and mTOR in pancreatic cancer have shown promising results based on their ability to impede cellular growth or delay tumor formation. This evidence concerns the gene MAP2K7 and familial pancreatic carcinoma.